BeiGene SSE – BeiGene Shanghai Investors

Our mission is to build the first next-generation biopharmaceutical company — one that expands the highest quality therapies to billions more people — through courage, persistent innovation, and challenging the status quo.

All Documents



Press Releases

Jan 19, 2023
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia    read more...
Jan 19, 2023
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA    read more...
Jan 18, 2023
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List    read more...
Press Releases

Thank you for your interest in Beigene, Ltd ! You will receive an email shortly. Please confirm your email address by clicking the link inside.

Back to the form